newsfilter
← Latest News
Earnings Call Transcripts·

OCSL 4Q2026 Earnings Call - OAKTREE SPECIALTY LENDING CORP

  • Financial Performance:

    • Fourth fiscal quarter adjusted net investment income (ANII) was $29.6 million ($0.34/share), down from $32.2 million ($0.37/share) in the prior quarter, driven by lower average portfolio balance and higher income-based incentive fees.
    • Full fiscal 2026 ANII totaled $131.7 million ($1.49/share), a decrease from $151.3 million ($1.76/share) in fiscal 2025.
    • Dividends declared were $0.32 per share ($0.30 base + $0.02 supplemental), totaling $1.39 per share for the full year, representing 108% of fiscal 2026 ANII.
    • Net leverage ended at 1.00x (range for fiscal 2026: 0.97x–1.07x), well within the long-term target of 0.9x–1.25x.
    • NAV per share was $15.63 as of September 30, 2026, a 0.4% decrease from June 2026 ($15.70).
    • Pro forma liquidity stood at approximately $689 million after the repayment of January 2027 notes; total liquidity was $1.04 billion prior to this repayment.
    • Total debt outstanding was $1.42 billion with a weighted average interest rate of 6.2% (6.4% pro forma including new 2031 notes).
    • Non-accruals stood at 1.8% of the total debt portfolio at fair value ($45 million), a 44% reduction from the prior year's $81 million.
  • Guidance and Future Outlook:

    • Fiscal 2027 priorities focus on resolving non-accruals, exiting non-income-producing equity positions, and redeploying proceeds into performing assets.
    • Management anticipates the September 25 basis point Fed rate hike to flow through to net investment income starting in the December quarter, with 91% of debt investments floating or swapped.
    • Every 25 basis point increase in base rates is expected to add approximately $0.02 per share in annualized adjusted net investment income once fully reset.
    • Leverage targets remain 0.9x–1.25x; the company is comfortable utilizing flexibility to deploy capital if attractive opportunities arise.
    • The company plans to maintain a staggered debt maturity profile with the next significant maturity in February 2029 following the repayment of January 2027 notes.
  • Business Segments and Product Lines:

    • New investment commitments totaled $179 million in the quarter, with the pipeline rebuilding in October ($80 million originated).
    • Weighted average yield on new debt investments was 9.6% (570 bps spread), wider than the market range of 500–550 bps.
    • Notable originations include a £600 million first-lien facility for Outcomes First Group (UK special needs education) and three new income-producing equity investments.
    • Equity exposure increased to 5.5% of fair value (from 3.9% last quarter), featuring structured downside protection.
    • Software represents 20% of the portfolio at fair value (down from 24% a year ago); 94% of software positions are first-lien, with high ARR risk exposure at ~3%.
    • Notable exits include the full repayment of the $35 million RumbleOn (RightNow Group) loan at 101 cents, and the sale of BioXL Therapeutics to Teva, with full milestone payments expected to exceed carrying marks.
  • Market and Competitive Landscape:

    • The market environment shifted from expectations of rate cuts to a "higher for longer" scenario with the Fed funds rate at 3.75%–4% and the 10-year Treasury yield exceeding 5%.
    • Direct lending volume rebounded slightly in September; capital remains competitive with supply and demand relatively balanced.
    • Spreads on new sponsor-backed first-lien loans held at SOFR + 500–550 bps, widening the premium over broadly syndicated loans to over 150 bps.
    • Corporate fundamentals remain resilient, though weakest leverage credits are facing strain; weighted average borrower interest coverage is 2.3x, remaining well above the 1.9x trough.
  • Risks and Challenges:

    • Key credit risks include idiosyncratic issues (e.g., ERP failures at a large opioid treatment center leading to non-accrual status) and specific company underperformance (e.g., Pluralsight).
    • Non-accruals include BioXL Therapeutics, which entered Chapter 11 but is expected to resolve quickly via a Teva acquisition.
    • Inflation pressures and elevated borrowing costs continue to strain leveraged credits, requiring careful interest coverage monitoring.
    • Management noted that 2021–2022 capital structures were not designed for base rates in the 4–5% range, though current non-accruals are largely driven by non-cyclical, idiosyncratic factors.
  • Management Commentary and Tone:

    • Tone was confident and disciplined, emphasizing successful resolution of previous credits and a focus on fundamental credit analysis over macro forecasting.
    • Management highlighted the success of the "flexible balance sheet" strategy, evidenced by the strong demand for the recent $300 million bond issuance (order book >3x deal size).
    • Executives expressed satisfaction with the incentive fee mechanism, which reduced fees by $16.1 million over the last year, aligning management compensation with shareholder returns.
    • CEO Armin Panossian stressed that while the macro backdrop is volatile, the portfolio is well-positioned with strong interest coverage and diversification.
  • Analyst Questions and Answers:

    • PIC Income Trend: Management attributed the sequential decline in PIK (Payment-in-Kind) income to moving BioXL to non-accruals and the exit of a royalty interest, rather than broad portfolio restructuring.
    • Capital Allocation: Management confirmed share repurchases are not a current priority due to the need for capital to deploy into attractive loans; leverage is expected to remain within the 0.97x–1.07x range seen in 2026.
    • Credit Quality: Executives clarified that current credit issues are largely idiosyncratic rather than cyclical, noting the stabilization of post-COVID normalization effects seen in 2021–2022.
  • Other Key Points:

    • Moody's revised OCSL's outlook to "stable" in August while maintaining the BAA3 rating.
    • The company successfully priced $300 million of 5-year unsecured notes due 2031 at a 7% coupon (240 bps spread over Treasuries).
    • Joint Ventures held $547 million in investments across 144 companies, generating an 11.5% return on equity for the quarter.
    • Unsecured debt now represents 88% of total debt (up from 65% last quarter), providing greater flexibility compared to secured leverage.
Company
OAKTREE SPECIALTY LENDING CORP
Keywords
OAKTREE SPECIALTY LENDING CORP